CY1112531T1 - Δραστικα για το κνς συντηγμενα δικυκλοετεροκυκλικα υποκατεστημενα αζαδικυκλικα αλκανιου παραγωγα - Google Patents

Δραστικα για το κνς συντηγμενα δικυκλοετεροκυκλικα υποκατεστημενα αζαδικυκλικα αλκανιου παραγωγα

Info

Publication number
CY1112531T1
CY1112531T1 CY20111101269T CY111101269T CY1112531T1 CY 1112531 T1 CY1112531 T1 CY 1112531T1 CY 20111101269 T CY20111101269 T CY 20111101269T CY 111101269 T CY111101269 T CY 111101269T CY 1112531 T1 CY1112531 T1 CY 1112531T1
Authority
CY
Cyprus
Prior art keywords
cyclots
bicyclehetic
cns
activities
synthesized
Prior art date
Application number
CY20111101269T
Other languages
English (en)
Inventor
Jianguo Ji
Tao Li
Christopher L Lynch
Murali Gopalakrishnan
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1112531T1 publication Critical patent/CY1112531T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/08—Diarylmethoxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αφορά συντηγμένα δικυκλοετεροκυκλικά υποκατεστημένα αζαδικυκλικά αλκανίου παράγωγα του τύπου (Ι) ή φαρμακευτικώς αποδεκτό άλας, εστέρα, αμίδιο ή προφάρμακο αυτών, όπου το η είναι 1, 2 ή 3, το Α είναι Ν ή Ν+-Ο- το R είναι υδρογόνο, αλκύλ, κυκλοαλκυλαλκύλ και αραλκύλ, το L επιλέγεται από την ομάδα που αποτελείται από Ο, S και -Ν(Ra)-, το Ar1 είναι 6-μελής αρυλ ή 6 μελής ετεροαρύλ δακτύλιος και το ΑR2 είναι δικυκλικό ετεροαρύλ και το Ra επιλέγεται από την ομάδα που αποτελείται από υδρογόνο, αλκύλ και αλκυλκαρβονύλ, υπό την προϋπόθεση ότι εάν το Ar2 είναι του τύπου (II), τότε το L είναι Ο ή S. Συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις και μεθόδους θεραπείας καταστάσεων και διαταραχών χρησιμοποιώντας τέτοιες ενώσεις και συνθέσεις.
CY20111101269T 2006-05-19 2011-12-20 Δραστικα για το κνς συντηγμενα δικυκλοετεροκυκλικα υποκατεστημενα αζαδικυκλικα αλκανιου παραγωγα CY1112531T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80219506P 2006-05-19 2006-05-19
EP07797473A EP2018380B1 (en) 2006-05-19 2007-05-15 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives

Publications (1)

Publication Number Publication Date
CY1112531T1 true CY1112531T1 (el) 2015-12-09

Family

ID=38662941

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101269T CY1112531T1 (el) 2006-05-19 2011-12-20 Δραστικα για το κνς συντηγμενα δικυκλοετεροκυκλικα υποκατεστημενα αζαδικυκλικα αλκανιου παραγωγα

Country Status (30)

Country Link
US (2) US7872017B2 (el)
EP (2) EP2018380B1 (el)
JP (3) JP5420398B2 (el)
KR (1) KR20090018972A (el)
CN (2) CN101448825A (el)
AT (1) ATE529423T1 (el)
AU (1) AU2007253950B2 (el)
BR (1) BRPI0711588A2 (el)
CA (1) CA2647830C (el)
CY (1) CY1112531T1 (el)
DK (1) DK2018380T3 (el)
EC (1) ECSP088918A (el)
ES (2) ES2525076T3 (el)
GT (1) GT200800248A (el)
HK (1) HK1122569A1 (el)
HR (1) HRP20110917T1 (el)
IL (1) IL195234A0 (el)
MX (1) MX2008014672A (el)
MY (1) MY147661A (el)
NO (1) NO20085153L (el)
NZ (2) NZ573735A (el)
PL (1) PL2018380T3 (el)
PT (1) PT2018380E (el)
RS (1) RS52062B (el)
RU (2) RU2437884C2 (el)
SI (1) SI2018380T1 (el)
TW (1) TWI343385B (el)
UA (1) UA92083C2 (el)
WO (1) WO2007137030A2 (el)
ZA (2) ZA200810687B (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7810743B2 (en) 2006-01-23 2010-10-12 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid delivery device
WO2009067586A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted diazabicycloalkane derivatives
CN101925599A (zh) * 2007-11-21 2010-12-22 雅培制药有限公司 作为烟碱性乙酰胆碱受体活性调节剂的联芳基取代的氮杂双环烷衍生物
MX2010007430A (es) 2008-01-11 2010-12-21 Albany Molecular Res Inc Piridoindoles (1-azinona)-sustituidos como antagonistas de la hormona de concentracion melanina humana.
US8389561B2 (en) * 2008-04-30 2013-03-05 Universiteit Gent Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
CA2638573C (en) 2008-04-30 2013-03-12 Universiteit Gent Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
AR075858A1 (es) 2009-03-18 2011-05-04 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US8809365B2 (en) * 2009-11-04 2014-08-19 Universiteit Gent 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders
AR079724A1 (es) * 2010-01-20 2012-02-15 Abbott Lab Metodos para el tratamiento del dolor
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
EA201391091A1 (ru) 2011-01-27 2013-12-30 Новартис Аг Применение активаторов никотиновых ацетилхолиновых рецепторов альфа-7
AU2012219537B2 (en) * 2011-02-25 2016-07-28 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR
WO2012127393A1 (en) 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
JO3766B1 (ar) 2011-10-20 2021-01-31 Novartis Ag منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
KR102043309B1 (ko) 2012-12-11 2019-11-11 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성의 예측 바이오마커
MX2015009153A (es) 2013-01-15 2016-03-04 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
CA2898080C (en) 2013-01-15 2018-01-09 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
BR112015016994A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN105636953B (zh) * 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
JP6612874B2 (ja) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換キヌクリジンアミド化合物
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
ES2927104T3 (es) 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
SG11202102406XA (en) 2018-09-13 2021-04-29 Bristol Myers Squibb Co Indazole carboxamides as kinase inhibitors
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
JP2022519637A (ja) * 2019-02-04 2022-03-24 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CN114007611A (zh) * 2019-02-04 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN114007614A (zh) * 2019-02-04 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113645970A (zh) * 2019-02-05 2021-11-12 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP2022521467A (ja) 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP2022519323A (ja) 2019-02-06 2022-03-22 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
TW202114680A (zh) 2019-08-06 2021-04-16 美商英塞特公司 Ｈｐｋ１抑制劑之固體形式
WO2023232917A1 (en) * 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Novel compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
GB8718445D0 (en) * 1987-08-04 1987-09-09 Wyeth John & Brother Ltd Pyridyl-ethers
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
EP0629190A1 (en) 1992-01-28 1994-12-21 Smithkline Beecham Plc Compounds as calcium channel antagonists
US5525613A (en) 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
NZ315677A (en) 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
EP1147112B1 (en) 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
EP1775297A3 (en) 1999-11-12 2008-12-03 Biogen Idec MA Inc. Adenosine receptor antagonists and methods of making and using the same
YU42903A (sh) 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina
EP1345603A4 (en) 2000-12-20 2004-09-08 Merck & Co Inc P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL
AU2002306848A1 (en) 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003062235A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
JP2005532368A (ja) 2002-06-12 2005-10-27 アボット・ラボラトリーズ メラニン濃縮ホルモン受容体の拮抗薬
TW200418856A (en) 2002-12-05 2004-10-01 Entropin Inc Novel tropane esters and methods for producing and using them
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CA2526285A1 (en) * 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
CA2530023A1 (en) 2003-06-24 2004-12-29 Neurosearch A/S Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
JP2008517064A (ja) * 2004-10-19 2008-05-22 アークル インコーポレイテッド Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
AU2006205066B2 (en) 2005-01-10 2012-05-17 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
JP2008526923A (ja) 2005-01-13 2008-07-24 ノイロサーチ アクティーゼルスカブ 新規８−置換８−アザ−ビシクロ［３．２．１］オクタン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用
MX2007010227A (es) * 2005-02-25 2007-11-07 Serenex Inc Derivados de tetrahidroindolona y tetrahidroindazolona.
US20060211686A1 (en) 2005-03-18 2006-09-21 Abbott Laboratories Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
EP1707202A1 (de) 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
TW200833687A (en) 2005-03-31 2008-08-16 Speedel Experimenta Ag Substituted piperidines
AU2006231646A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-Met modulators and methods of use
US20060258691A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
CA2610560C (en) * 2005-06-03 2013-04-02 Alfa Wassermann, Inc. Fraction collector
EP1933920A4 (en) * 2005-10-11 2010-12-29 Flowmedica Inc VESSEL WITH VARIABLE LUMEN CONSTRUCTION
PE20071159A1 (es) 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
US7605170B2 (en) * 2005-12-01 2009-10-20 N.V. Organon 8-azabicyclo[3.2.1]octane derivatives
TW200806662A (en) * 2005-12-01 2008-02-01 Organon Nv 8-azabicyclo[3.2.1]octane derivatives
DE602007011897D1 (de) * 2006-02-15 2011-02-24 Sanofi Aventis Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
CN101384605A (zh) * 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 新的氨基醇取代的芳基噻吩并嘧啶酮、其制备方法以及其作为药物的用途
CN101925599A (zh) * 2007-11-21 2010-12-22 雅培制药有限公司 作为烟碱性乙酰胆碱受体活性调节剂的联芳基取代的氮杂双环烷衍生物
GB0800760D0 (en) * 2008-01-16 2008-02-27 Syngenta Participations Ag Fungicidal compositions

Also Published As

Publication number Publication date
MX2008014672A (es) 2009-03-09
PL2018380T3 (pl) 2012-05-31
MY147661A (en) 2012-12-31
EP2018380A2 (en) 2009-01-28
WO2007137030A2 (en) 2007-11-29
RU2011120802A (ru) 2012-11-27
ATE529423T1 (de) 2011-11-15
AU2007253950A1 (en) 2007-11-29
CN102516241B (zh) 2015-07-29
TW200813045A (en) 2008-03-16
EP2431368A1 (en) 2012-03-21
AU2007253950B2 (en) 2012-05-03
ES2525076T3 (es) 2014-12-17
IL195234A0 (en) 2009-08-03
NZ573735A (en) 2011-10-28
SI2018380T1 (sl) 2012-02-29
BRPI0711588A2 (pt) 2011-11-16
US20080045539A1 (en) 2008-02-21
JP2014058506A (ja) 2014-04-03
EP2018380B1 (en) 2011-10-19
ECSP088918A (es) 2008-12-30
RS52062B (en) 2012-06-30
JP2009537562A (ja) 2009-10-29
RU2437884C2 (ru) 2011-12-27
KR20090018972A (ko) 2009-02-24
CA2647830A1 (en) 2007-11-29
PT2018380E (pt) 2012-01-17
JP5420398B2 (ja) 2014-02-19
EP2431368B1 (en) 2014-08-27
HRP20110917T1 (hr) 2012-03-31
NZ589784A (en) 2012-05-25
WO2007137030A3 (en) 2008-07-24
CN102516241A (zh) 2012-06-27
CN101448825A (zh) 2009-06-03
US20100305089A1 (en) 2010-12-02
ZA201001298B (en) 2012-01-25
UA92083C2 (ru) 2010-09-27
US7872017B2 (en) 2011-01-18
NO20085153L (no) 2008-12-11
ZA200810687B (en) 2010-05-26
ES2373792T3 (es) 2012-02-08
JP5834051B2 (ja) 2015-12-16
TWI343385B (en) 2011-06-11
CA2647830C (en) 2016-02-09
HK1122569A1 (en) 2009-05-22
JP2016053056A (ja) 2016-04-14
GT200800248A (es) 2009-12-02
DK2018380T3 (da) 2012-01-23
RU2008150331A (ru) 2010-06-27

Similar Documents

Publication Publication Date Title
CY1112531T1 (el) Δραστικα για το κνς συντηγμενα δικυκλοετεροκυκλικα υποκατεστημενα αζαδικυκλικα αλκανιου παραγωγα
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
WO2008112939A3 (en) Composition and method for making oligo-benzamide compounds
MY148253A (en) Azaadamantane derivatives and methods of use
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
WO2007127317A3 (en) Humanized c-kit antibody
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
MY153719A (en) Prokineticin 1 receptor antagonists
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
MX2010007392A (es) Antagonistas de trpa1.
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
MX2010007391A (es) Antagonistas de trpa1.
WO2009055629A3 (en) Cyclohexeneamide derivatives and their use as trpv1 antagonist
WO2008147812A3 (en) 4&#39; substituted compounds having 5-ht6 receptor affinity
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
MX2010005650A (es) Derivados de diazabicicloalcano substituidos con biarilo.
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
ATE417816T1 (de) Anilinohexafluoroisopropanol verbindungen